First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules - A Case Report

The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2022-03, Vol.42 (3), p.1339-1344
Main Authors: Salkini, Mohamad W, Yang, Xuqing, Hashmi, Fayyaz Haider, Kandzari, Stanley J, Hogan, Thomas, Morley, Chad, Zekan, David, Werner, Zachary, Williams, Dorian J, Guo, Y I, Matthew, Thomas Lewis, Spangler, Michael, Yu, Jing Jie
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Bladder
Bladder cancer
Bone marrow
Cancer
Capsules
Carcinoma, Papillary - drug therapy
Carcinoma, Papillary - pathology
Case reports
Chemotherapy
Cisplatin
Cytology
Drug Combinations
Glutamates - administration & dosage
Humans
Intravenous administration
Invasiveness
Male
Muscles
Organoplatinum Compounds - administration & dosage
Patients
Remission
Remission (Medicine)
Side effects
Time Factors
Treatment Outcome
Tumors
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - pathology
Urothelial carcinoma
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent mass was observed in July 2021. The patient received DCP capsules for seven weeks with no significant side-effects. Complete blood count with differential and a basic metabolic panel showed no adverse effects of DCP capsules on the bone marrow, liver or renal parameters. Cystoscopy after oral DCP found no evident bladder tumors; cytology was negative for high-grade urothelial carcinoma. In this patient, DCP-capsules appeared to be as effective as DCP-IV for achieving bladder cancer remission. Both forms of DCP chemotherapy are convenient, active against several cancer types, with decreased adverse effects compared to cisplatin. Both have been available for treating cancer patients in China. A USA clinical trial of DCP in bladder and other cancers appears warranted.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.15602